| Identification | Back Directory | [Name]
4-Quinolinecarboxamide, 2-(4-ethoxyphenyl)-N-[3-(2-methyl-1-piperidinyl)propyl]- | [CAS]
689270-18-6 | [Synonyms]
Feeblin
IRF5-IN-1
4-Quinolinecarboxamide, 2-(4-ethoxyphenyl)-N-[3-(2-methyl-1-piperidinyl)propyl]- | [Molecular Formula]
C27H33N3O2 | [MOL File]
689270-18-6.mol | [Molecular Weight]
431.57 |
| Chemical Properties | Back Directory | [Boiling point ]
627.0±55.0 °C(Predicted) | [density ]
1.108±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
13.59±0.46(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
IRF5-IN-1 (compound C5) is an IRF5 pathway-specific inhibitor. IRF5-IN-1 significantly reduces IRF5 nuclear translocation without affecting the activation of NF-κB p65. IRF5-IN-1 acts through SLC15A4 to selectively inhibit TLR7/8-induced IRF5 responses in cells[1]. | [References]
[1] Andras Boeszoermenyi, et al. A conformation-locking inhibitor of SLC15A4 with TASL proteostatic anti-inflammatory activity. Nat Commun. 2023 Oct 20;14(1):6626. DOI:10.1038/s41467-023-42070-3 |
|
|